- Home
- CQP vs ROIV Comparison
CQP vs ROIV Comparison
Compare CQP & ROIV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CQP | ROIV |
|---|---|---|
| Founded | 2003 | 2014 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Oil/Gas Transmission | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 29.3B | 26.2B |
| IPO Year | 2006 | 2021 |
Fundamental Metrics
Financial Performance| Metric | CQP | ROIV |
|---|---|---|
| Price | $68.72 | $36.16 |
| Analyst Decision | Sell | Strong Buy |
| Analyst Count | 7 | 9 |
| Target Price | ★ $60.43 | $28.94 |
| AVG Volume (30 Days) | 107.2K | ★ 5.0M |
| Earning Date | 05-07-2026 | 05-28-2026 |
| Dividend Yield | ★ 5.05% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.07 | N/A |
| Revenue | ★ $10,758,000,000.00 | $8,260,000.00 |
| Revenue This Year | $6.35 | N/A |
| Revenue Next Year | $1.27 | $744.61 |
| P/E Ratio | $983.86 | ★ N/A |
| Revenue Growth | ★ 23.60 | N/A |
| 52 Week Low | $49.53 | $11.54 |
| 52 Week High | $70.64 | $37.00 |
Technical Indicators
Market Signals| Indicator | CQP | ROIV |
|---|---|---|
| Relative Strength Index (RSI) | 61.27 | 59.70 |
| Support Level | $61.69 | $33.01 |
| Resistance Level | $70.64 | $36.35 |
| Average True Range (ATR) | 2.16 | 1.24 |
| MACD | 0.33 | 0.10 |
| Stochastic Oscillator | 100.00 | 87.01 |
Price Performance
Historical ComparisonAbout CQP Cheniere Energy Partners LP
Cheniere Energy Partners is a liquified natural gas producer operating one facility in Sabine Pass, Louisiana. It generates most of its revenue through long-term contracts with customers on a fixed- and variable-fee payout structure. It also generates revenue by selling uncontracted LNG to customers on a short or one-time basis. The profit generated through those activities is split with parent and operator Cheniere Energy.
About ROIV Roivant Sciences Ltd.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.